You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH):上半年營收增長85.88%至5.75億元
格隆匯 08-28 18:04

格隆匯8月28日丨君實生物(688180.SH)披露2020年半年度報告,報告期內,公司實現營業收入5.75億元,比去年同期增長了85.88%,其中核心產品特瑞普利單抗2020年上半年實現銷售收入為4.26億元,當期毛利率為89.84%。同時,公司繼續加大新藥開發力度,研發投入7.09億元,較去年同期增長92.25%。

2020年初,全球範圍內的新型冠狀病毒大流行對公司的整體運營帶來了一定考驗。包括商業銷售、監管互動和檢查、臨牀試驗招募和參與等多環節工作任務或暫停或延遲。第一季度面臨公共衞生危機時,公司迅速採取防疫應對措施,保護員工安全,保證患者用藥。同時,公司盡力協調各部門維持正常運轉,努力減少項目延誤和資金損失,各項業務已於第二季度逐漸恢復正常。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account